Geode Capital Management LLC Sells 44,584 Shares of DaVita Inc. $DVA

Geode Capital Management LLC reduced its stake in shares of DaVita Inc. (NYSE:DVA) by 4.4% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 978,790 shares of the company’s stock after selling 44,584 shares during the period. Geode Capital Management LLC’s holdings in DaVita were worth $111,016,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of DVA. Invesco Ltd. increased its stake in shares of DaVita by 2.0% in the third quarter. Invesco Ltd. now owns 1,679,248 shares of the company’s stock worth $223,122,000 after purchasing an additional 32,358 shares during the period. Dimensional Fund Advisors LP boosted its holdings in DaVita by 8.8% during the third quarter. Dimensional Fund Advisors LP now owns 1,085,593 shares of the company’s stock valued at $144,230,000 after purchasing an additional 88,061 shares in the last quarter. LSV Asset Management boosted its holdings in DaVita by 1.1% during the fourth quarter. LSV Asset Management now owns 936,768 shares of the company’s stock valued at $106,426,000 after purchasing an additional 9,739 shares in the last quarter. Arrowstreet Capital Limited Partnership boosted its holdings in shares of DaVita by 109.7% in the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 553,809 shares of the company’s stock worth $73,585,000 after acquiring an additional 289,725 shares in the last quarter. Finally, Neuberger Berman Group LLC boosted its holdings in shares of DaVita by 138.5% in the 3rd quarter. Neuberger Berman Group LLC now owns 463,250 shares of the company’s stock worth $61,502,000 after acquiring an additional 269,015 shares in the last quarter. 90.12% of the stock is currently owned by institutional investors.

Insider Transactions at DaVita

In related news, CFO Joel Ackerman sold 51,471 shares of the business’s stock in a transaction on Thursday, May 7th. The shares were sold at an average price of $192.10, for a total value of $9,887,579.10. Following the transaction, the chief financial officer owned 132,434 shares in the company, valued at $25,440,571.40. The trade was a 27.99% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 1.50% of the stock is currently owned by insiders.

DaVita Trading Up 0.1%

Shares of DVA opened at $192.28 on Friday. The firm’s 50 day moving average is $171.47 and its 200-day moving average is $143.18. The stock has a market capitalization of $12.34 billion, a PE ratio of 17.84, a P/E/G ratio of 0.63 and a beta of 0.91. DaVita Inc. has a 12 month low of $101.00 and a 12 month high of $202.69.

DaVita (NYSE:DVA) last issued its earnings results on Tuesday, May 5th. The company reported $2.87 earnings per share for the quarter, beating analysts’ consensus estimates of $2.33 by $0.54. The firm had revenue of $3.42 billion for the quarter, compared to analyst estimates of $3.36 billion. DaVita had a net margin of 5.65% and a negative return on equity of 270.37%. The company’s quarterly revenue was up 6.0% on a year-over-year basis. During the same quarter last year, the business posted $2.00 earnings per share. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. Equities research analysts predict that DaVita Inc. will post 15.07 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have recently commented on the company. Deutsche Bank Aktiengesellschaft raised DaVita from a “hold” rating to a “buy” rating and boosted their target price for the stock from $126.00 to $220.00 in a report on Wednesday, May 6th. Barclays boosted their price objective on shares of DaVita from $158.00 to $194.00 and gave the stock an “equal weight” rating in a research report on Thursday, May 7th. UBS Group boosted their price objective on shares of DaVita from $190.00 to $235.00 and gave the stock a “buy” rating in a research report on Thursday, May 7th. TD Cowen upped their price objective on shares of DaVita from $144.00 to $201.00 and gave the company a “hold” rating in a research report on Monday, May 11th. Finally, Zacks Research raised shares of DaVita from a “hold” rating to a “strong-buy” rating in a research note on Thursday, May 7th. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $199.17.

DaVita Profile

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.